Janux Therapeutics (JANX) Current Leases (2021 - 2026)

Janux Therapeutics (JANX) has 6 years of Current Leases data on file, last reported at $2.5 million in Q1 2026.

• Current Leases for Q1 2026 came in at $2.5 million, up 36.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.5 million (up 36.5% YoY), and the FY2025 annual result was $2.4 million, up 36.82% from the prior year.
• Current Leases rose to $2.5 million in Q1 2026 per JANX's latest filing, from $2.4 million in the prior quarter.
• Over five years, Current Leases peaked at $2.5 million in Q1 2026 and troughed at $88000.0 in Q2 2022.
• A 5-year average of $1.5 million and a median of $1.6 million in 2024 frame the typical range for Current Leases.
• The sharpest annual moves came in 2023 and 2025: Current Leases soared 1500.0% in 2023, then increased 14.91% in 2025.
• A 5-year view of Current Leases shows it stood at $763000.0 in 2022, then jumped by 98.82% to $1.5 million in 2023, then increased by 15.29% to $1.7 million in 2024, then jumped by 36.82% to $2.4 million in 2025, then increased by 3.3% to $2.5 million in 2026.
• Business Quant data shows JANX's Current Leases at $2.5 million in Q1 2026, $2.4 million in Q4 2025, and $2.3 million in Q3 2025.